Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature

Table 1 Cases of synchronous MM and CML recorded in literature so far

Age (Yr)/Sex	Diagnosis interval (month)	MM			CML		Study
Age (Yr)/Sex	Diagnosis interval (month)	Type	Bone lesion	Chemotherapy	WBC count	Chemotherapy	Study
CML + MM
58/M	0	IgGκ	Yes	MP	140	HU, BU TG	[20,21,22]
72/F	0	IgGκ	Yes	IFN, VDS and PD	162.4	IFN, HU	[20,21,22]
81/M	0	IgAκ	Yes	MP	28.7	NR	[20,21,22]
66/M	0	IgGκ	Yes	MP	171	HU, BU, IFN	[20,21,22]
85/F	0	IgGλ	Yes	NR	8.1	NR	[20,21,22]
71/F	0	IgGκ	No	MP, BD, Len, Cyc	12.7	IM	[20,21,22]
64/F	0	IgAκ	No	BD	27.2	IM	[20,21,22]
88/M	0	IgDκ	No	Len, BD	40	IM	[22]
77/M	0	IgAλ	NR	BR	6.2	NR	[22, 23]
64/M	0	IgAλ	Yes	Thal, Dex	13.1	NT	[24]
MM → CML
77/M	33	BJP	No	NT	145	6-MP	[20,21,22]
71/M	24	IgGκ	Yes	MP	40.8	HU	[20,21,22]
70/M	33	IgGκ	No	NR	25.2	HU	[20,21,22]
47/M	33	BJPκ	Yes	NR	23.9	NR	[20,21,22]
68/M	54	IgGλ	Yes	VCR, Dox, Dex, zol	11.81	IM	[21]
62/F	17	IgGκ	No	BD, Cyc, Dox, Len	NR	DA	[20]
60/M	48	IgGκ	Yes	Len, BD	11.2	DA	[22, 25]
51/F	3	IgG	Yes	BD	NR	IM	[26]
76/M	28	IgGκ	Yes	Len, Dex	35.8	DA, BO	[27]
68/M	24	IgAκ	NR	Cyc, Thal	NR	IM	[28]
CML → MM
65/F	113	IgGκ	Yes	BU, PM	43	BU, PM	[20,21,22]
71/M	38	BJPλ	NR	NR	NR	IM	[20,21,22]
68/M	20	IgGλ	No	MP	NR	IFN, IM	[20,21,22]
76/M	14	IgAλ	No	MP	NR	IFN, IM	[20,21,22]
57/F	65	IgAλ	NR	Thal, BD, VCR, Dox	52.38	IM	[20,21,22]
72/F	3	IgGκ	No	NT	31.3	IM	[20,21,22]
63/F	120	IgGκ	NR	BD, Len	17.8	IM	[21]
76/M	38	IgAλ	No	NT	18.8	IM	[29]
58/M	137	IgGκ	Yes	BD, Len, Thal	NR	IM	[30]
85/M	61	IgGκ	No	MP	171.8	IM, NL	Present case

6-MP: 6-mercaptopurine, BD: bortezomib and dexamethasone, BJP: Bence jones protein, BO: bosutinib, BR: bortezomib, BU: busulphan, CML: chronic myelogenous leukemia, Cyc: cyclophosphamide, DA: dasatinib, Dex: dexamethasone, Dox: doxorubicin, F: female, HU: Hydroxyurea, IFN: interferonalpha, IM: imatinib, Len: lenalidomide, M: male, MM: multiple myeloma, MP: melphalan and prednisolone, NL: nilotinib, NR: not reported, NT: no treatment, PD: prednisolone, PM: phenylalanine mustard TG: thioguanine, Thal: thalidomide, VCR: Vincristine, VDS: Vindesine sulfate

ISSN: 1752-1947